According to the supplemental announcement, KINTOR PHARMACEUTICAL (9939) clarified that the anti-hair loss foam product is part of the company’s cosmetic brand KOSHINÉ, which features KX-826 as a core ingredient. The cosmetics sales business is reported to be small and ancillary when compared with the company’s primary development and commercialization focus on KX-826, GT20029, and other pipeline products.

The company noted that the sales target of RMB100 million, mentioned previously, is a long-term and cumulative goal rather than a near-term objective. In terms of resource allocation, out of a total of 121 employees, 69 are engaged in drug research and development, supply, and GMP production, while 24 are involved in cosmetics sales as well as marketing and sales preparations for drug candidates. R&D expenses are expected to exceed 50% of total expenses for 2025, driven primarily by ongoing Phase II and Phase III clinical studies of KX-826 on androgenetic alopecia in China and the Phase II clinical study of GT20029 on Acne Vulgaris.

The announcement also stated that cosmetic business cashflow will be directed to support the company’s medical and biological development. The company remains consistent in its listing business direction and believes it has sufficient resources, with active negotiations underway for potential bank facilities by the first quarter of 2026, alongside equity financing discussions with potential investors. KINTOR PHARMACEUTICAL (9939) anticipates these measures will provide ample liquidity for continued operations, research activities, and commercialization preparations of its core products.